Nocturnal Enuresis in ChildrenNCT06771128
Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis
A study testing Ginkgo Biloba oral tablet and Desmopressin Acetate 0.2 mg Tablets in people with Nocturnal Enuresis in Children and Desmopressin, run by Menoufia University at 1 site in Egypt.
Trial summary
the efficacy of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis Read more about this study
- Who is it for?
- Ages 5 to 18 years
- Conditions the study is for
- Nocturnal Enuresis in Children, Desmopressin, Monosymptomatic Nocturnal Enuresis
- What is being tested?
- Ginkgo Biloba oral tablet and Desmopressin Acetate 0.2 mg Tablets
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 398 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Nov 2024to 1 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- all children with monosymptomatic nocturnal enuresis.
Who cannot join
- children with day and night wetting.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Ginkgo Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis: A Randomized Prospective Study
the efficacy of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis
Read the detailed description
Bedwetting among children is a common disorder, affecting 30% at age 4, 10% at age 6, 3% at age 12, and 1% at age. Untreated, the spontaneous cure rate is about 15% a year. Treatment is dominated by two approaches, enuresis alarm and drugs.
Treatment with drugs has largely been focused on tricyclic antidepressants especially imipramine or, more recently, antidiuretic agents such as desmopressin. For imipramine the proportion of total remission is 10-50% during treatment and a long term cure in 5-40%. However, numerous reports of side effects, some lethal, have led to a decline in its use.
One of theory of nocturnal enuresis is deep sleep in children, this the main cornerstone in using Alarm as line of management.
On the other hand drugs used in re-habitation of sleep rhythm seems to be with great benefits in management as GINKGO BILOBA.
Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States. Its purported biological effects include: scavenging free radical; lowering oxidative stress; reducing neural damages, reducing platelets aggregation; anti-inflammation; anti-tumor activities; anti-aging, and improve night sleep rhythm.
the aim of this study is to evaluate the effect of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis.
- Being tested
- Ginkgo Biloba oral tablet, Desmopressin Acetate 0.2 mg Tablets, Ginkgo Biloba like Placebo, Desmopressin like Placebo
- Keywords
- monosymptomatic nocturnal enuresis, nocturnal enuresis, desmopressin, Ginkgo Biloba
- Medical subject headings
- Nocturnal Enuresis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ginkgo Biloba oral tabletDrug
patients receive Ginkgo Biloba oral tablet 120 mg once daily
Desmopressin Acetate 0.2 mg TabletsDrug
patient receives desmopressin 0.2 mg oral tablet once daily
Ginkgo Biloba like PlaceboDrug
patients receive Ginkgo Biloba like Placebo oral tablet once daily
Desmopressin like PlaceboDrug
patients receive Desmopressin like Placebo oral tablet once daily
| Study group | Role | What they receive |
|---|---|---|
| Ginkgo Biloba group | Experimental | Patients in this group receive Ginkgo Biloba oral tablet. Receives: Drug: Ginkgo Biloba oral tablet; Drug: Desmopressin like Placebo |
| Desmopressin group | Active comparator | Patients in this group receive Desmopressin oral tablets. Receives: Drug: Desmopressin Acetate 0.2 mg Tablets; Drug: Ginkgo Biloba like Placebo |
| Combination group | Experimental | Patients in this group receive both Ginkgo Biloba and desmopressin oral tablets. Receives: Drug: Ginkgo Biloba oral tablet; Drug: Desmopressin Acetate 0.2 mg Tablets |
| Placebo group | Placebo comparator | Patients in this group receive Placebo oral tablet. Receives: Drug: Ginkgo Biloba like Placebo; Drug: Desmopressin like Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Night wetting frequency
Night wetting frequency is measured by the number of wet nights per week.
Measured: 1, 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2025
- Study start1 Nov 2024
- Primary completion1 Dec 2025
- Study completion1 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nocturnal Enuresis in ChildrenStudies of the same condition, open and under way.
- More trials run by Menoufia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 398 participants (actual)
Sponsor and investigators
- Lead sponsor
- Menoufia University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ammar Fathi Mohamed AlOrabi, Menoufia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06771128
- Sponsor's protocol ID
- Ginkgo Biloba vs Desmopressin
- Status last verified
- Sep 2025
- First submitted
- 7 Jan 2025
- Last updated
- 13 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ginkgo Biloba Versus Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis: A Randomized Prospective Study
- ClinicalTrials.gov ID
- NCT06771128
- Acronym / sponsor ID
- Ginkgo Biloba vs Desmopressin
- Keywords
- monosymptomatic nocturnal enuresis, nocturnal enuresis, desmopressin, Ginkgo Biloba
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 398 participants (actual)
- Lead sponsor
- Menoufia UniversityUniversity, hospital or other
- Study start
- 1 Nov 2024 (actual)
- Primary completion
- 1 Dec 2025 (actual)
- Study completion
- 1 Jan 2026 (actual)
- First posted
- 13 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
the efficacy of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis
Detailed description
Bedwetting among children is a common disorder, affecting 30% at age 4, 10% at age 6, 3% at age 12, and 1% at age. Untreated, the spontaneous cure rate is about 15% a year. Treatment is dominated by two approaches, enuresis alarm and drugs.
Treatment with drugs has largely been focused on tricyclic antidepressants especially imipramine or, more recently, antidiuretic agents such as desmopressin. For imipramine the proportion of total remission is 10-50% during treatment and a long term cure in 5-40%. However, numerous reports of side effects, some lethal, have led to a decline in its use.
One of theory of nocturnal enuresis is deep sleep in children, this the main cornerstone in using Alarm as line of management.
On the other hand drugs used in re-habitation of sleep rhythm seems to be with great benefits in management as GINKGO BILOBA.
Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States. Its purported biological effects include: scavenging free radical; lowering oxidative stress; reducing neural damages, reducing platelets aggregation; anti-inflammation; anti-tumor activities; anti-aging, and improve night sleep rhythm.
the aim of this study is to evaluate the effect of Ginkgo Biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Ginkgo Biloba group | Experimental | Drug: Ginkgo Biloba oral tablet, Drug: Desmopressin like PlaceboPatients in this group receive Ginkgo Biloba oral tablet. |
| Desmopressin group | Active comparator | Drug: Desmopressin Acetate 0.2 mg Tablets, Drug: Ginkgo Biloba like PlaceboPatients in this group receive Desmopressin oral tablets. |
| Combination group | Experimental | Drug: Ginkgo Biloba oral tablet, Drug: Desmopressin Acetate 0.2 mg TabletsPatients in this group receive both Ginkgo Biloba and desmopressin oral tablets. |
| Placebo group | Placebo comparator | Drug: Ginkgo Biloba like Placebo, Drug: Desmopressin like PlaceboPatients in this group receive Placebo oral tablet. |
Who may qualify
- Ages
- 5 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- all children with monosymptomatic nocturnal enuresis.
Key exclusion criteria (1 listed)
- children with day and night wetting.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ginkgo Biloba oral tabletpatients receive Ginkgo Biloba oral tablet 120 mg once daily | Drug | Combination group, Ginkgo Biloba group |
| Desmopressin Acetate 0.2 mg Tabletspatient receives desmopressin 0.2 mg oral tablet once daily | Drug | Combination group, Desmopressin group |
| Ginkgo Biloba like Placebopatients receive Ginkgo Biloba like Placebo oral tablet once daily | Drug | Desmopressin group, Placebo group |
| Desmopressin like Placebopatients receive Desmopressin like Placebo oral tablet once daily | Drug | Ginkgo Biloba group, Placebo group |
Primary outcome
Night wetting frequency
Time frame: 1, 3 months
Night wetting frequency is measured by the number of wet nights per week.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
Related trials for Nocturnal Enuresis in Children
Recruiting
Effectiveness of Individualized Pelvic Floor Muscle Rehabilitation in Addition to Standard Urotherapy and Alarm Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis
Primary Monosymptomatic Nocturnal Enuresis
Not yet recruiting
Potential Adjuvant Therapies for Children With Primary Nocturnal Enuresis
Nocturnal Enuresis in Children, Primary Nocturnal Enuresis
Active, not recruitingPhase 3
Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in Children
Treatment of Non-monosymptomatic Nocturnal Enuresis
Not yet recruiting
Sleep in Children Placed in Out-of-home Care
Sleep Problems, Parasomnias
Recruiting
Bedtime Device Restriction and Desmopressin in PMNE.
Primary Monosymptomatic Nocturnal Enuresis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ginkgo Biloba oral tablet and Desmopressin Acetate 0.2 mg Tablets in people with Nocturnal Enuresis in Children and Desmopressin, run by Menoufia University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Night wetting frequency (time frame: 1, 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.